ClinicalTrials.Veeva

Menu

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Sun Pharma logo

Sun Pharma

Status and phase

Completed
Phase 3

Conditions

Keratoconjunctivitis Sicca

Treatments

Drug: OTX-101 0.09%

Study type

Interventional

Funder types

Industry

Identifiers

NCT02845674
OTX-101-2016-002

Details and patient eligibility

About

This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)

Enrollment

258 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Completion of Study OTX-101-2016-001

Exclusion criteria

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

258 participants in 1 patient group

OTX-101 0.09%
Experimental group
Description:
0.09% cyclosporine nanomicellar solution
Treatment:
Drug: OTX-101 0.09%

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems